ConvertibleCAR-T, A Highly Adaptable CAR-T Platform to Fight HIV

One potential approach to achieving a functional HIV cure is to first reduce the size of the HIV reservoir and then engineer an immune response that can effectively control the shrunken reservoir in the absence of antiretroviral therapy. MicAbodies, comprised of full-length broadly neutralizing HIV antibodies coupled to a mutated ligand, selectively engage a mutant receptor that has been engineered as a chimeric antigen receptor (CAR) and expressed on CD8 T cells (convertibleCAR-T cells). The HIV-specific MicAbodies and the convertibleCAR-T cells can detect and eliminate HIV infected cells. The modularity of the convertibleCAR-T cell system allows multiplexing with several anti-HIV antibodies and yields greater breadth and control, thus making this platform a promising tool for attacking the latent HIV reservoir.

During this webinar, we will discuss:

The potential approach to achieving a functional HIV cure.

How does convertibleCAR-T detect and eliminate HIV infected cells?

The performance of the convertibleCAR-T cells ex vivo and in vivo.

ConvertibleCAR-T cells' advantages over conventional CAR-T cells.


Eytan Herzig, Ph.D.

Staff Research Scientist
Gladstone Center for HIV Cure Research
University of California, San Francisco

You can add this webinar to you calendar now by clicking on the icon below.

Speaker Bio

Dr. Eytan Herzig is a Staff Research Scientist in the Gladstone Center for HIV Cure Research, where he leads the use of new technologies to fight HIV. After completing his Ph.D. education at the Tel Aviv University, he worked as a postdoctoral fellow at Tel Aviv University and at Gladstone.

Click here to join a Webex test and make sure your device is compatible with the webinar software.

Richiedi un'offerta

Via Umbria 10
20090 Segrate (Milano)

Tel. +39 02-26922300
Fax +39 02-26926058
Fax +39 02-26923535

If you no longer wish to receive these announcements click here